Intra-Cellular Therapies, Inc. (ITCI) reported third-quarter 2024 loss of 25 cents per share, wider than the Zacks Consensus Estimate of a loss of 18 cents. The company had incurred a loss of 25 cents per share in the year-ago quarter. Total revenues, comprising product sales and grant revenues, came in at $175.4 million, up 39% year over year. The top line beat the Zacks Consensus Estimate of $172 million. ITCI's Q3 Results in Detail Caplyta, the only approved drug in Intra-Cellular's portfolio, was approv ...